Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)
BACKGROUND: We previously reported the good feasibility and favorable efficacy of perioperative capecitabine plus oxaliplatin (CapeOx) in patients (pts) with clinical T3(SS)/T4a(SE) N1-3 M0 gastric cancer (GC) in a phase II study in which the pathological response rate, the primary endpoint, of 54.1...
Main Authors: | Akamaru, Y. (Author), Endo, S. (Author), Fujita, S. (Author), Fujitani, K. (Author), Goto, M. (Author), Imano, M. (Author), Kato, T. (Author), Kawabata, R. (Author), Kawakami, H. (Author), Kurokawa, Y. (Author), Lee, S.-W (Author), Matsuyama, J. (Author), Sakai, D. (Author), Satoh, T. (Author), Shimokawa, T. (Author), Taniguchi, H. (Author), Tatsumi, M. (Author), Terazawa, T. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
NLM (Medline)
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
by: Renata Ferrarotto, et al.
Published: (2013-09-01) -
Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
by: Yu S, et al.
Published: (2020-10-01) -
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial
by: Chin, K., et al.
Published: (2022) -
Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
by: Yuanyuan Yu, et al.
Published: (2021-05-01) -
Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
by: Tsutomu Namikawa, et al.
Published: (2018-02-01)